Business
European patent grant for Parsortix
European patent grant for Parsortix.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 4749R Angle PLC 09 March 2016 \n\n\n\n\n\nFor immediate release\n\n\n 9 March 2016\n\n\n\n\n \nANGLE plc (\"the Company\")\n \nEUROPEAN PATENT GRANT FOR PARSORTIX\n \nStrengthens Patent-Protected Product in Growing Liquid Biopsy Market\n \nANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that it has been granted a European patent for its Parsortix liquid biopsy system, which harvests cancer cells from blood for medical analysis. \n \nThe granted European patent provides protection over a wide range of uses of the Parsortix technology and extends the duration of patent coverage out to 2034. Granted patents have already been secured in the United States, Canada, China and Australia. Corresponding patent applications have been made worldwide in countries considered to represent substantial markets for Parsortix products. \n \nRecently the liquid biopsy market has been identified by several major US investment banks as an emerging multi-billion dollar market. ANGLE's Parsortix system is one of a limited number of patent protected, product-based, liquid biopsy solutions. Most other businesses addressing the liquid biopsy market are service-based and often have little or no patent protection. ANGLE believes its Parsortix system, which harvests live circulating tumour cells, is highly differentiated and has the potential to play a leading role in the liquid biopsy market. \n \nThe Company is pursuing a strategy to strengthen the breadth and duration of its patent coverage across major markets worldwide to maximise the commercial returns that can be achieved from its Parsortix technology. New patent applications will continue to be made in all territories consistent with this strategy. \n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented:\n \n\"The grant of this patent in the European Union further strengthens ANGLE's IP position and maintains our momentum in expanding patent coverage across major markets worldwide. Securing granted patents for our Parsortix liquid biopsy system is a crucial element of our strategy, enabling ANGLE to pursue a scalable, product-based business model and provide our customers with the in-house capability to reliably har...